Immunothrombosis and COVID-19-a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital

Imagem de Miniatura
Arquivos
art_LIMA_Immunothrombosis_and_COVID19a_nested_posthoc_analysis_from_a_2023.PDF (791.72 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Autores
Citação
CLINICS, v.78, article ID 100178, 7p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: COVID-19 is associated with an elevated risk of thromboembolism and excess mortality. Difficulties with best anticoagulation practices and their implementation motivated the current analysis of COVID-19 patients who developed Venous Thromboembolism (VTE). Method: This is a post-hoc analysis of a COVID-19 cohort, described in an economic study already published. The authors analyzed a subset of patients with confirmed VTE. We described the characteristics of the cohort, such as demographics, clinical status, and laboratory results. We tested differences amid two subgroups of patients, those with VTE or not, with the competitive risk Fine and Gray model. Results: Out of 3186 adult patients with COVID-19, 245 (7.7%) were diagnosed with VTE, 174 (5.4%) of them dur-ing admission to the hospital. Four (2.3% of these 174) did not receive prophylactic anticoagulation and 19 (11%) discontinued anticoagulation for at least 3 days, resulting in 170 analyzed. During the first week of hospitaliza-tion, the laboratory most altered results were C-reactive protein and D-dimer. Patients with VTE were more criti-cal, had a higher mortality rate, worse SOFA score, and, on average, 50% longer hospital stay. Conclusion: Proven VTE incidence in this severe COVID-19 cohort was 7.7%, despite 87% of them complying completely with VTE prophylaxis. The clinician must be aware of the diagnosis of VTE in COVID-19, even in patients receiving proper prophylaxis.
Palavras-chave
COVID-19, Biomarkers, Cohort studies, Venous thromboembolism, Immunothrombosis
URI
https://observatorio.fm.usp.br/handle/OPI/54807
Referências
  1. Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
  2. Agarwal G, 2022, THER ADV CARDIO DIS, V16, DOI 10.1177/17539447221105013
  3. ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933
  4. Burn E, 2022, LANCET INFECT DIS, V22, P1142, DOI 10.1016/S1473-3099(22)00223-7
  5. Castillo-Perez M, 2021, THROMB J, V19, DOI 10.1186/s12959-021-00346-y
  6. Clayton TC, 2011, INT J EPIDEMIOL, V40, P819, DOI 10.1093/ije/dyr012
  7. Coleman JJ, 2013, INT J QUAL HEALTH C, V25, P564, DOI 10.1093/intqhc/mzt044
  8. Couturaud F, 2002, BLOOD COAGUL FIBRIN, V13, P241, DOI 10.1097/00001721-200204000-00010
  9. Frantzeskaki F, 2017, RESPIRATION, V93, P212, DOI 10.1159/000453002
  10. Gaertner F, 2016, SEMIN IMMUNOL, V28, P561, DOI 10.1016/j.smim.2016.10.010
  11. Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMoa2103417]
  12. Gonc alves FAR, 2021, CLINICS, V76, P3547
  13. Jenner WJ, 2021, J THROMB THROMBOLYS, V51, P595, DOI 10.1007/s11239-021-02394-7
  14. Kyriakoulis KG, 2022, CURR VASC PHARMACOL, V20, P96, DOI 10.2174/1570161119666210824160332
  15. Lambden S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2663-7
  16. LAWLER PR, 2021, THERAPEUTIC ANTICOAG, DOI 10.1056/NEJMOA2105911
  17. Lazaridis D, 2022, J PHARM PRACT, V35, P1000, DOI 10.1177/08971900211015055
  18. Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
  19. Louis SG, 2014, JAMA SURG, V149, P365, DOI 10.1001/jamasurg.2013.3963
  20. Mai V, 2021, VASC PHARMACOL, V139, DOI 10.1016/j.vph.2021.106882
  21. Manne BK, 2020, BLOOD, V136, P1317, DOI 10.1182/blood.2020007214
  22. Miethke-Morais A, 2021, BRAZ J INFECT DIS, V25, DOI 10.1016/j.bjid.2021.101609
  23. Mohamed MFH, 2021, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.598846
  24. Nakanishi T, 2021, J CLIN INVEST, V131, DOI [10.1172/JCI152386, 10.1101/2021.03.07.21252875]
  25. Nopp S, 2020, RES PRACT THROMB HAE, V4, P1178, DOI 10.1002/rth2.12439
  26. Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
  27. R Core Team, 2020, R LANG ENV STAT COMP
  28. Ribeiro DD, 2012, J THROMB HAEMOST, V10, P1179, DOI 10.1111/j.1538-7836.2012.04732.x
  29. Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
  30. Signorelli C, 2020, INT J PUBLIC HEALTH, V65, P1435, DOI 10.1007/s00038-020-01486-0
  31. Strekerud Finn, 1998, Tidsskrift for den Norske Laegeforening, V118, P3934
  32. Tan BK, 2021, THORAX, V76, P970, DOI 10.1136/thoraxjnl-2020-215383
  33. Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768
  34. Tromboembolismo Venoso., 2009, REV ASS ME DICA BRAS, V55, P102
  35. von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120
  36. Yu YA, 2020, ANN PALLIAT MED, V9, P1257, DOI 10.21037/apm.2020.04.05

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/11
Carregar mais